Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 idelalisib study in rituximab- and alkylating agent-refractory indolent B-cell non-Hodgkin lymphoma
2010-022155-33Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Feb 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of idelalisib in mature B-cell lymphoma and non-Hodgkin lymphoma (NHL), sponsored by Gilead Sciences. Primary endpoint: Overall response rate. Started Feb 2011; status: completed.
02
Drugs
idelalisib
03
Conditions
mature B-cell lymphomanon-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2010-022155-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022155-33.